NCT05640453 Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting
| NCT ID | NCT05640453 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Tanta University |
| Condition | Pregabalin |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2022-12-15 |
| Primary Completion | 2026-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 70 participants in total. It began in 2022-12-15 with a primary completion date of 2026-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to determine the effect of pregabalin versus dexmedetomidine on the treatment and lasting duration of delirium in fast tracking elderly patients after Coronary Artery Bypass Grafting.
Eligibility Criteria
Inclusion Criteria: * CABG patients ≥ 65 years of age both genders American Society of Anesthesiologists (ASA) physical status classification II or III planned for fast track developed postoperative delirium (POD). Exclusion Criteria: * Patients who had history of psychiatric diseases; inability to communicate; * previous history of POD; preoperative sick sinus syndrome, allergy/sensitivity to pregabalin or dexmedetomidine, severe bradycardia (heart rate \<50 beat per minute), second-degree or above atrioventricular block without pacemaker; severe hepatic or renal insufficiency. * Previous cardiac or thoracic surgery, known diagnosis of depression or other major psychiatric diseases, cognitive impairment or inability to cooperate with the study, renal insufficiency, and history of substance abuse.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05640453 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Pregabalin. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05640453 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT05640453 currently recruiting?
Yes, NCT05640453 is actively recruiting participants. Contact the research team at eslam.morsy@med.tanta.edu.eg for enrollment information.
Where is the NCT05640453 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT05640453 clinical trial?
NCT05640453 is sponsored by Tanta University. The trial plans to enroll 70 participants.